Novartis DRC A multicenter, randomized, double-masked Phase 3a study to assess safety and efficacy of brolucizumab 6mg dosed Q4 weeks compared to Q8 weeks in high anti-VEGF-need patients with neovascular age-related macular degeneration (nAMD)